The danger zone: Systematic review of the role of HMGB1 danger signalling in traumatic brain injury

The danger zone: Systematic review of the role of HMGB1 danger signalling in traumatic brain injury

Background: Traumatic brain injuries (TBI) are associated with complex inflammatory pathways that lead to the development of secondary injuries such as cerebral ischaemia, elevated intracranial pressure and cognitive deficits. The association between intracellular danger signalling involving nuclear...

Full description

Saved in:
Bibliographic Details
Published in:Brain injury Vol. 31; no. 1; pp. 2 - 8
Main Authors: Parker, Taylor M., Nguyen, Austin Huy, Rabang, Joshua R., Patil, Arun-Angelo, Agrawal, Devendra K.
Format: Journal Article
Language:English
Published: England Taylor & Francis 02-01-2017
Subjects:
biomarkers
Brain - metabolism
brain injuries
Brain Injuries, Traumatic - metabolism
HMGB1 protein
HMGB1 Protein - metabolism
Humans
inflammation
Inflammation - metabolism
Neurons - metabolism
prognosis
Signal Transduction - physiology
brain injuries
inflammation
HMGB1 protein
prognosis
biomarkers
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Traumatic brain injuries (TBI) are associated with complex inflammatory pathways that lead to the development of secondary injuries such as cerebral ischaemia, elevated intracranial pressure and cognitive deficits. The association between intracellular danger signalling involving nuclear chromatin-binding factor, high mobility group box-1 (HMGB1) and inflammatory pathways following TBI has not yet been fully understood. Primary objective: To comprehensively review the available literature regarding the potential diagnostic, prognostic and therapeutic use of HMGB1 in TBI. Methods: A systematic literature review of studies available in PubMed using human and animal subjects was performed. A total of eight studies were included in the results. Conclusions: A comprehensive review of these reports demonstrated that, following TBI, HMGB1 is released from damaged neurons and is elevated in patient's serum and CSF. Furthermore, these studies showed the potential for HMGB1 to serve as a prognostic biomarker and therapeutic target in patients with TBI. Thus, HMGB1 is a prospective candidate for future studies as it shows promise in treating and/or predicting the sequelae of TBI.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-4
ObjectType-Undefined-1
content type line 23
ObjectType-Review-2
ObjectType-Article-3
ISSN:0269-9052
1362-301X
DOI:10.1080/02699052.2016.1217045